enkephalin, d-penicillamine (2,5)- has been researched along with anandamide in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buchalla, R; Jergas, B; Kurz, CM; Lutz, B; Redmer, A; Schlicker, E; Schulte, K; Steingrüber, N; Zimmer, A | 1 |
1 other study(ies) available for enkephalin, d-penicillamine (2,5)- and anandamide
| Article | Year |
|---|---|
Cannabinoid CB1 receptor activation, pharmacological blockade, or genetic ablation affects the function of the muscarinic auto- and heteroreceptor.
Topics: Analgesics, Opioid; Animals; Arachidonic Acid; Arachidonic Acids; Cerebral Cortex; Cholinergic Neurons; Endocannabinoids; Enkephalin, D-Penicillamine (2,5)-; Glycerides; GTP-Binding Protein alpha Subunits; Hippocampus; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Muscarinic Agonists; Oxotremorine; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Receptors, Muscarinic; Receptors, Opioid, delta; Rimonabant; Synaptosomes; Vas Deferens | 2012 |